ChondroCelect
Withdrawn
This medicine's authorisation has been withdrawn
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
MedicineHumanWithdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 29 July 2016, the European Commission withdrew the marketing authorisation for ChondroCelect (characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins) in the European Union (EU), which will become effective as of 30 November 2016. The withdrawal was at the request of the marketing authorisation holder, TiGenix NV, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.
ChondroCelect was granted marketing authorisation in the EU on 5 October 2009 for repair of single symptomatic cartilaginous defects. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2014.
The European Public Assessment Report (EPAR) for ChondroCelect is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.
Product information
Latest procedure affecting product information:
IAIN/012/G
29/07/2016
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- ChondroCelect
- Active substance
- characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
- International non-proprietary name (INN) or common name
- characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
- Therapeutic area (MeSH)
- Cartilage Diseases
- Anatomical therapeutic chemical (ATC) code
- M09AX02
Pharmacotherapeutic group
Other drugs for disorders of the musculo-skeletal systemTherapeutic indication
Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.
Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².
This page was last updated on